Maria Tsirogianni
Athens, ESYE31, Greece
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Myeloma Elderly Prognostic Score (MEPS): A Proposed Prognostic Score Integrating Age, Renal Function, Performance Status, and Ultra-High-Risk Cytogenetics.
Journal: American journal of hematology
Published: March 23, 2026
Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma.
Journal: In vivo (Athens, Greece)
Published: March 01, 2022
Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
Journal: Hematological oncology
Published: December 23, 2020
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.
Journal: Annals of hematology
Published: November 17, 2020
Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine.
Journal: Leukemia & lymphoma
Published: April 06, 2019
Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.
Journal: European journal of haematology
Published: April 04, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026